Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Repozitorij Univerze v Ljubljani
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Napredno
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Podrobno
Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
ID
Ruiz-López, Eduardo
(
Avtor
),
ID
Jovchevska, Ivana
(
Avtor
),
ID
Schuhmacher, Alberto J.
(
Avtor
), et al.
PDF - Predstavitvena datoteka,
prenos
(3,75 MB)
MD5: 7B67331F8C6054C442BD8C039522F155
URL - Izvorni URL, za dostop obiščite
https://www.nature.com/articles/s41598-022-27161-3
Galerija slik
Izvleček
The cancer "omics" reveal many clinically relevant alterations that are transforming the molecular characterization of glioblastomas. However, many of these findings are not yet translated into clinical practice due, in part, to the lack of non-invasive biomarkers and the limitations imposed by the blood-brain barrier. Nanobodies, camelid single-domain antibody fragments, emerge as a promising tool for immunotargeted applications for diagnosing and treating glioblastomas. Performing agnostic bioinformatic analysis from glioblastoma patient datasets, we identified ATP Binding Cassette subfamily C member 3 (ABCC3) as a suitable target for immunotargeted applications. The expression of ABCC3 is associated with poor survival and impaired response to temozolomide. Importantly, high expression of ABCC3 is restricted to glioblastoma, with negligible levels in healthy brain tissue, and further correlates with tumor grade and stemness markers. We identified three immunogenic epitopes of ABCC3 which were used to isolate nanobodies from a glioblastoma-specific phage-display nanobody library. Two nanobodies targeting ABCC3 (NbA42 and NbA213) were further characterized and demonstrated in vivo selective recognition of ABCC3 in glioblastoma xenograft mouse models upon systemic administration. We designate NbA42 and NbA213 as new candidates to implement immunotargeted applications guiding a more personalized and precise diagnosis, monitoring, and treatment of glioblastoma patients.
Jezik:
Angleški jezik
Ključne besede:
glioblastoma
,
nanobodies
,
immunotargeted applications
,
antibody fragment therapy
,
biologics
,
CNS cancer
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2022
Št. strani:
12 str.
Številčenje:
Vol. 12, art. 22581
PID:
20.500.12556/RUL-165165
UDK:
616-006
ISSN pri članku:
2045-2322
DOI:
10.1038/s41598-022-27161-3
COBISS.SI-ID:
136531971
Datum objave v RUL:
26.11.2024
Število ogledov:
447
Število prenosov:
278
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Scientific reports
Skrajšan naslov:
Sci. rep.
Založnik:
Nature Publishing Group
ISSN:
2045-2322
COBISS.SI-ID:
18727432
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
glioblastom
,
nanotelesa
,
imunsko usmerjene aplikacije
Projekti
Financer:
Instituto de Salud Carlos III
Program financ.:
Fondo de Investigación en Salud
Številka projekta:
PI18/01665
Financer:
Instituto de Salud Carlos III
Program financ.:
Fondo de Investigación en Salud
Številka projekta:
PI21/00441
Financer:
EC - European Commission
Program financ.:
ERDF, A way to make Europe
Financer:
Fundación FERO
Program financ.:
XIII Beca FERO en Investigación Oncológica Traslacional
Financer:
ASPANOA - Asociación de Padres de Niños con Cáncer de Aragón
Program financ.:
Ayudas a la investigación del cáncer infantil
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Proyectos líneas prioritarias y de carácter multidisciplinar de la RIS3 2021–2023 DGA
Številka projekta:
LMP248_21
Financer:
Asociación Española de Cáncer de Mama Metastásico
Program financ.:
Metapremio
Financer:
AECC - Asociación Española Contra el Cáncer
Program financ.:
Ayuda Predoctoral-Aragón
Financer:
AECC - Asociación Española Contra el Cáncer
Program financ.:
Fundación Científica
Številka projekta:
PRDAR17002RUIZ
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Ibercaja-CAI Research Fellowships program
Številka projekta:
CM 5/19
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
Z3-1869
Naslov:
Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj